Novartis acquire Admune, a clinical-stage biotech company focused on the development and delivery of cytokine therapy drugs for cancer, for the company’s IL-15 agonist program, currently in Phase I clinical trials for metastatic cancer. The fee is not being disclosed. Novartis also signed a $15 million licensing agreement with Palobiofarma. The company, based at Barcelona’s science park, focuses on the discovery and development of new drugs based on the modulation of adenosine receptors.
A preliminary research presented at a US medical conference suggests that cancer drug may be helpful in improving memory and motor skills in patients with Parkinson's disease. The trial at Georgetown University involved 12 people who had Parkinson's or a related condition called Lewy body dementia.
Amgen, a biopharmaceutical company, has entered a neuroscience collaboration with Novartis in the areas of Alzheimer's disease and migraine. The collaboration also enables Amgen to focus on the commercialisation of its migraine programmes in the US, Canada and Japan, while leveraging Novartis' strong commercial capabilities in neuroscience throughout Europe and other markets worldwide.
Do Not Forget to Verify
(Click on Subscription link in your inbox)
--------
Also Join: 
.png)
